| Toggle SummaryJune 16, 2020
|
GenMark Diagnostics Chosen as Primary Provider of Rapid Diagnostic Testing for Vidant Health
Largest health system in eastern North Carolina turns to ePlex® platform for fast results on SARS-CoV-2, respiratory and blood stream infections CARLSBAD, Calif. , June 16, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular
|
View HTML
|
| Toggle SummaryMay 27, 2020
|
GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , May 27, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
|
View HTML
|
| Toggle SummaryMay 11, 2020
|
GenMark Diagnostics Announces Closing of $80 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CARLSBAD, Calif. , May 11, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
|
View HTML
|
| Toggle SummaryMay 6, 2020
|
GenMark Prices Public Offering of Common Stock
CARLSBAD, Calif. , May 06, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
|
View HTML
|
| Toggle SummaryMay 6, 2020
|
GenMark Commences Public Offering of Common Stock
CARLSBAD, Calif. , May 06, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
|
View HTML
|
| Toggle SummaryMay 4, 2020
|
GenMark Diagnostics Reports First Quarter 2020 Results
CARLSBAD, Calif. , May 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. ("GenMark" or the "Company") (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended March 31, 2020 .
|
View HTML
|
| Toggle SummaryMay 4, 2020
|
GenMark Diagnostics Announces Scott Mendel Appointed CEO
CARLSBAD, Calif. , May 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that Scott Mendel has been appointed President and Chief Executive Officer effective immediately.
|
View HTML
|
| Toggle SummaryApril 22, 2020
|
GenMark Diagnostics to Report First Quarter 2020 Financial Results on May 4, 2020
CARLSBAD, Calif. , April 22, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its first quarter earnings results after market close on Monday, May 4, 2020. Management will hold a conference call to review the company's financial performance
|
View HTML
|
| Toggle SummaryApril 7, 2020
|
GenMark Diagnostics Provides Preliminary Financial and Operational Results for First Quarter 2020 and Increases 2020 Revenue Guidance
First Quarter 2020 Revenue Expected to Represent Approximately 80% Year-Over-Year Growth CARLSBAD, Calif. , April 07, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary
|
View HTML
|
| Toggle SummaryMarch 23, 2020
|
GenMark Awarded BARDA Grant for the Development of ePlex® RP2 Panel
CARLSBAD, Calif. , March 23, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has been awarded a grant from the Biomedical Advanced Research and Development Authority (BARDA), part
|
View HTML
|
